Cefamandole

Cefamandole (Cephamandole) s a semi-synthetic second-generation cephalosporin antibiotic with broad-spectrum antimicrobial activity. Cefamandole is resistant to hydrolysis by β-lactamases produced by some Gram-negative bacteria. Cefamandole kills Gram-positive cocci and various Gram-negative bacilli mainly by inhibiting cell wall synthesis, but it is inactive against Pseudomonas, Proteus vulgaris and Providencia stuartii, and its efficacy is affected by inoculum size. The plasma elimination half-life of Cefamandole in rats is only 0.4 h, it is mainly excreted in urine in biologically active form, and it hardly penetrates the non-inflamed blood-brain barrier. Cefamandole is widely used in studies related to bacterial infections^{[1][2][3][4][5]}. In Vitro:Cefamandole (30 μg/mL; 0-12 h) is hydrolyzed by beta-lactamases from Enterobacter cloacae, Serratia marcescens, and Proteus morganii, allowing bacterial growth to resume after hydrolysis is complete, while Pseudomonas aeruginosa grows despite cefamandole presence prior to hydrolysis^[1].
Cefamandole (0.12-64 μg/mL; 18 h) inhibits 90-100% of methicillin-susceptible S. aureus, group A and B streptococci, S. pneumoniae, N. gonorrhoeae, H. influenzae, and S. typhosa^[3]. In Vivo:Cefamandole, administered as a single subcutaneous dose of 100 mg/kg to male Long‑Evans rats, reaches a peak plasma concentration of 49 μg/mL at 0.5 h and has a plasma half‑life of 0.4 h^[4]. Cefamandole, given as a single intravenous dose of 50 mg/kg to male Sprague‑Dawley rats, exhibits free‑drug pharmacokinetic properties consistent with a two‑compartment model, with an elimination half‑life of 21.6 min^[5].